Prosecution Insights
Last updated: November 20, 2026
Application No. 18/467,134

COMPLEX OR SALT THEREOF, AND METHOD FOR PRODUCING THE SAME

Non-Final OA §112
Filed
Sep 14, 2023
Priority
Mar 16, 2021 — JP 2021-042918 +1 more
Examiner
DICKENS, AMELIA NICOLE
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ajinomoto Co., Inc.
OA Round
1 (Non-Final)
48%
Grant Probability
Moderate
1-2
OA Rounds
3m
Est. Remaining
70%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
61 granted / 128 resolved
-12.3% vs TC avg
Strong +22% interview lift
Without
With
+22.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
58 currently pending
Career history
186
Total Applications
across all art units

Statute-Specific Performance

§101
6.5%
-33.5% vs TC avg
§103
22.2%
-17.8% vs TC avg
§102
20.6%
-19.4% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 128 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice of New Examiner Please note that the correspondence for this application has changed (see Conclusion section at the end). Election/Restrictions Claim 1 (and other claims) is directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 22-24, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 9 Apr 2026 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Status The amended claim set filed 9 June 2026 is acknowledged. Claims 1-24 are currently pending. Of those, claims 22-24 are currently amended, and no claims are new. No claims are cancelled. Claims 1-24 will be examined on the merits herein. Priority The application claims priority to foreign priority document JP2021-042918 (filed 16 March 2021) and is a CON of PCT/JP2022/011534 (filed 15 March 2022). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. However, support for the claimed subject matter in the foreign priority document cannot be assessed because an English translation has not been filed. So for the sake of searching the art, the effective filing date used is 15 March 2022 for all claims. The Office is not requiring that the foreign priority document be translated, but applicant cannot rely upon the earlier date from the certified copy of the foreign priority application to overcome an art rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Information Disclosure Statement The information disclosure statements (IDS) submitted on 14 Sep 2023 and 1 Aug 2025 were filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. Signed copies of these statements are attached with this action. Specification The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The following title is suggested: Ferritin and IgG complex of salt thereof, and method for producing the same. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 19 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 19 reads “The complex or salt thereof according to claim 13, wherein the modifying group comprises a functional substance.” The term “functional substance” is not defined in the specification and the broadest reasonable interpretation is any function. This does not limit claim 13 because a “modifying group” necessarily has the function of modifying the ferritin, so all modifying groups are functional substances. Therefore, claim 19 does not further limit claim 13. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 20 is not rejected because it limits claims 19 and 13 to being certain functional substances. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-7, 9-11, and 18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 3, the claim reads “natural type”. The specification defines this term as follows: “As used herein, the term “natural-type” indicates that the amino acid sequence is natural-type.” [0120]. The specification also states: “The natural-type human ferritin H chain is typically a polypeptide comprising the amino acid sequence of SEQ ID NO: 1.” [0120], but this is not a limiting definition because of “typically”. One of ordinary skill in the art would not be able to determine whether a protein is “natural-type” without a definition of the term. In the interest of compact prosecution, in this action, the claim scope was considered to include any ferritin H chain. Also regarding claim 3, the claim reads “which may lack a methionine residue at position 1.” MPEP 2143.03 states: “Language that suggests or makes a feature or step optional but does not require that feature or step does not limit the scope of a claim under the broadest reasonable claim interpretation.” The claim is indefinite because one of ordinary skill in the art would not be able to determine whether the presence of a methionine is an optional feature that does not limit the scope of the claim, or whether this statement is describing a modification to the “natural-type” ferritin H chain that would expand the scope beyond “natural-type” ferritin H chain. In the interest of compact prosecution, in this action, the claim scope was considered to include any ferritin H chain. Regarding claim 4, the claim reads “via an atom in the side chain of amino acid residues present at the same position in the human ferritin H chain contained therein”. The term “same position” is a relative term that is indefinite in the absence of a reference point. Additionally, it is unclear what must be the “same”. The claim appears to be comparing positions of atoms in a side chain as being “the same” as the position in a ferritin H protein. The claim and specification do not explain how to compare these two different objects to determine whether or not they are the same. In the interest of compact prosecution, in this action, the claim scope was considered to include any position. It appears that this one phrase might be combining two different limitations, perhaps the claim is intended to be interpreted as saying that linkers L1 and L2 are linked via an atom in the amino acid side chain of the human ferritin H chain, and also wherein there is an additional limitation about some things being the same. Claims 5-7 and 9-11 are also rejected because they depend from claim 4 and do not obviate this grounds of rejection. Regarding claim 7, the claim reads “wherein the cysteine residue is present at position 91 and/or position 103”. The claim scope is indefinite because a limitation that the cysteine residue is at both position 91 and 103 appears to be inconsistent with the limitation of parent claim 4 that the atom be present in the same position in the human ferritin H chain. However, one of ordinary skill in the art would not be able to interpret whether the limitation is truly inconsistent due to the indefiniteness of the limitation in claim 4 relating the “same position.” Clarification is requested. Also regarding claim 7, the claim reads “position… according to the reference position of the natural-type human ferritin H chain.” The term “natural-type” is not clearly defined in the specification or claim (see specification’s definition quoted in par. 14 above). As “natural-type human ferritin H chain” is not a defined sequence, it cannot serve as a reference for amino acid position. Therefore, the amino acid positions are indefinite because they lack a reference. Regarding claim 9, the claim reads “atom in the side chain of amino acid residues present at the same position in the two heavy chain constant regions”. This limitation is analogous to the limitation of claim 4 and is indefinite for the same reasons (see par. 16). Claims 10-11 are also rejected because they depend from claim 9 and do not obviate this grounds of rejection. Regarding claim 11, the claim reads “the lysine residue is present at position 246/248, 288/290, or 317 of the IgG antibody heavy chain according to EU numbering.” EU numbering of IgG antibody heavy chains are known to the art, such as at the IMGT scientific chart (2001; PTO-892). The EU numbering scheme does not have positions with slashes in them, so position names 246/248 and 288/290 are indefinite because they are not present in the claimed reference numbering. In the interest of compact prosecution, the claim is examined using all of the five positions listed (246, 248, 288, 290, and 317). Regarding claim 18, the relevant text is copied following the paragraph. The claim is indefinite because the box is a clear error, but does not have a clear correction. The box is presumed to be a special character that was not correctly interpreted. Correction is requested. PNG media_image1.png 32 172 media_image1.png Greyscale Allowable Subject Matter Claims 1-2, 8, 12-17, and 21-24 are allowed. Claim 20 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The art at the time of filing teaches IgG-ferritin complexes where there are multiple IgGs per ferritin particle, but not complexes where there are two ferritins and one IgG. For example, Khoshnejad et al. (2018, “Ferritin nanocages…”; made of record in IDS filed 14 Sep 2023) teaches a ferritin complex that can bear 3-4 IgG molecules per ferritin nanocage (Abstract) and also teaches complexes made with lower molar ratios that have “attachment of 1.26, 2.81, and 3.46 antibodies per hFTL-5X [ferritin] nanocarrier at for molar ratios of 1:2, 1:5, and 1:10, respectively” (pg. 1212 col. 2 par. 1). Lin et al. (US 20080292545 A1; made of record in IDS filed 14 Sep 2023) teaches functionalized apoferritin particles that are bound to at least two preselected antibodies [claims 1 and 4]. One of ordinary skill in the art would not find it obvious to make this modification to attach one antibody to multiple different ferritin complexes in the absence of a teaching in the art. Additionally, the claimed complex is unlikely to occur stochastically when mixing IgG and ferritin according to the methods of the art. Rudick et al. (1984, “Preparation of monoclonal…”, Abstract only; PTO-892) teaches mixing antibody and ferritin with a molar ratio of 1:1.4, among the lowest ratios tested in the art, and found that the product contained “over 90% ferritin-IgG "monomers”” (Abstract) rather than a mixture of antibody-ferritin complexes with different ratios that might include the claimed 1 IgG: 2 ferritin complex. In fact, no complexes were found to have a 1:2 IgG: ferritin ratio as claimed when testing mixing at different molar ratios (Table 1). Therefore, the claimed product is both novel and non-obvious. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMELIA N DICKENS whose telephone number is (571)272-0381. The examiner can normally be reached M-F 8:30-4:30 (EDT/EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. AMELIA N DICKENS Examiner Art Unit 1645 /AMELIA NICOLE DICKENS/Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

Sep 14, 2023
Application Filed
Nov 03, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781182
BACILLUS SUBTILIS FNFH_BS08 AND USE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12751984
COMPOSITION CONTAINING A YEAST FOR PREVENTING SIMPLE AND/OR RECURRING CYSTITIS
4y 10m to grant Granted Oct 06, 2026
Patent 12748112
NEW SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS
4y 4m to grant Granted Sep 29, 2026
Patent 12740583
SYNERGISTIC BLENDS OF PROBIOTICS EXPRESSING IMPROVED BENEFICIAL ACTIVITY FOR HUMAN HOST FAVOURABLY INTERACTING WITH FOOD, PARTICULARLY BABY FOOD
4y 4m to grant Granted Sep 22, 2026
Patent 12724025
Method for Detecting Urinary Tract Infections and Sample Analysis Using Liquid Chromatography
5y 9m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
48%
Grant Probability
70%
With Interview (+22.5%)
3y 6m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 128 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month